I’m just college student who has spent more time reading biotech clinical trial protocols than studying for my exams. I’m $30k+ deep into this. I am a regard, and this is a casino. And yeah this is written by ai but its my research im lazy and not getting paid to write this sue me.
The TL;DR
Viridian Therapeutics ($VRDN) just dropped god-tier Phase 3 data (REVEAL-2), gap-up pumped the stock, and then immediately "upsized" a capital raise to build a $1.1 BILLION liquid to push their new drug. The banks just bought millions of shares at $17.00 and cant sell until $26. Right now, the stock is trading at $16.89. You can literally buy the dip cheaper than the billionaires did.
1. The Data:
Last week, VRDN released results for their TED drug (Chronic Thyroid Eye Disease).
- The Result: p < 0.0001. They didn't just beat the placebo; they vaporized it.
- The Competition: They are coming for Amgen’s Tepezza (a multi-billion dollar monopoly). VRDN’s drug is safer, has way fewer side effects (no hearing loss), and is building an at-home injector so patients don't have to sit in a hospital chair for 4 hours.
- The Outcome: This is "Best-in-Class" medicine. Period.
2. The "Institutional Floor" (Buying Below the Banks)
- The Offering: They just closed an upsized $350 MILLION raise today.
- The Price: The institutions (the people who actually know how to read balance sheets) just agreed to buy at $17.00.
- The Arbitrage: We are currently trading BELOW the offering price. Usually, retail is the "exit liquidity" for the banks. This time, the banks are the floor for us.
- The Convertible Clue: They issued notes with a conversion price of $24.65. The banks are literally betting $225M that this stock hits $25+ in the near future.
3. The Catalyst: JUNE 30 MOONSHOT 🌙
The REVEAL-2 data was just the appetizer. The real play is the June 30 PDUFA date for their lead drug, Veligrotug.
- Priority Review: The FDA is fast-tracking this.
- The Setup: With $1.1B in cash, VRDN is "uncrashable." They are fully funded for a global launch. If the FDA says "Yes" on June 30, this stock doesn't just go to $20; it hits the analyst targets of $34.00+.
Check my profile if u think this is my first time spotting a moon shot. Will answer any questions in the comments.